Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,500 |
Ending reported balance
After 2026-06-29 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-06-26 · Exercise / conversion · Acquired 7,732 · Balance 14,232 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 Row 2 · 2026-06-26 · Sale · Disposed 7,732 · Balance 6,500 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F2: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-06-29 · Exercise / conversion · Acquired 22,268 · Balance 28,768 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 Row 4 · 2026-06-29 · Sale · Disposed 22,268 · Balance 6,500 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F4: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2035-01-23 | Direct | 52,268 |
Reported balance
After 2026-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-26 · Exercise / conversion · Disposed 7,732 · Balance 52,268 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F3: The options vested 100% on December 31, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2035-01-23 | Direct | 30,000 |
Reported balance
After 2026-06-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-29 · Exercise / conversion · Disposed 22,268 · Balance 30,000 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F3: The options vested 100% on December 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025
F2: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: The options vested 100% on December 31, 2025.
F4: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2018 Filed Jun 14, 2018 20:32 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 30,918 | $7.79 | $240,916.15 |
DisclosureSEC source: 0001179022-18-000051 · edgar.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F3 · price: The shares were sold in multiple transactions at prices ranging from $6.52 to $8.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 20:32 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 25,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001179022-18-000051 · edgar.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:32 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 12,780 | $6.50 | $83,070.00 |
DisclosureSEC source: 0001179022-18-000051 · edgar.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,374 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 20:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,760 | $6.50 | $69,940.00 |
DisclosureSEC source: 0001179022-18-000049 · edgar.xml · nonDerivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,154 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 29,294 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001179022-18-000049 · edgar.xml · derivative · entry 6 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,706 Underlying: Common Stock · 29,294 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F3 · derivative.exercise_date: The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000049 · edgar.xml · derivative · entry 5 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F2 · derivative.exercise_date: The options vest as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 104,294 | $5.77 | $602,047.54 |
DisclosureSEC source: 0001179022-18-000049 · edgar.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,914 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F4 · price: The shares were sold in multiple transactions at prices ranging from $5.50 to $6.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 29,294 | $1.37 | $40,132.78 |
DisclosureSEC source: 0001179022-18-000049 · edgar.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 50,000 | $0.87 | $43,500.00 |
DisclosureSEC source: 0001179022-18-000049 · edgar.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 08, 2018 Filed Jun 18, 2018 20:44 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001179022-18-000055 · edgar.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The options vest as follows: 25% on June 30, 2018, 25% on September 30, 2018, and 50% on December 31, 2018. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 25,701 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · derivative · entry 10 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,701 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F3 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 75,190 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · derivative · entry 9 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,190 shares Expires 2022-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F2 · derivative.exercise_date: The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 100,891 | $5.21 | $525,268.81 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · nonDerivative · entry 6 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,914 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F4 · price: The shares were sold in multiple transactions at prices ranging from $5.15 to $5.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 25,701 | $0.87 | $22,359.87 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · nonDerivative · entry 5 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 75,190 | $2.32 | $174,440.80 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · nonDerivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 4,898 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · derivative · entry 8 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,701 Underlying: Common Stock · 4,898 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F3 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 4,180 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · derivative · entry 7 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,190 Underlying: Common Stock · 4,180 shares Expires 2022-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F2 · derivative.exercise_date: The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 9,078 | $5.15 | $46,751.70 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,914 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 4,898 | $0.87 | $4,261.26 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:33 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 4,180 | $2.32 | $9,697.60 |
DisclosureSEC source: 0001179022-18-000047 · edgar.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 4,294 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · derivative · entry 10 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,599 Underlying: Common Stock · 4,294 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F3 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 5,630 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · derivative · entry 9 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,370 Underlying: Common Stock · 5,630 shares Expires 2022-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F2 · derivative.exercise_date: The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 9,924 | $5.16 | $51,183.03 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · nonDerivative · entry 6 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,914 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F5 · price: The shares were sold in multiple transactions at prices ranging from $5.15 to $5.18. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 4,294 | $0.87 | $3,735.78 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · nonDerivative · entry 5 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 5,630 | $2.32 | $13,061.60 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · nonDerivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 5,407 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · derivative · entry 8 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,893 Underlying: Common Stock · 5,407 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F3 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 5,500 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · derivative · entry 7 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 5,500 shares Expires 2022-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F2 · derivative.exercise_date: The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,907 | $5.15 | $56,173.23 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,914 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F4 · price: The shares were sold in multiple transactions at prices ranging from $5.15 to $5.16. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 5,407 | $0.87 | $4,704.09 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 20:31 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 5,500 | $2.32 | $12,760.00 |
DisclosureSEC source: 0001179022-18-000046 · edgar.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 59,700 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000044 · edgar.xml · derivative · entry 8 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,300 Underlying: Common Stock · 59,700 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F3 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 9,500 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179022-18-000044 · edgar.xml · derivative · entry 7 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,500 Underlying: Common Stock · 9,500 shares Expires 2022-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F2 · derivative.exercise_date: The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 69,200 | $5.10 | $352,920.00 |
DisclosureSEC source: 0001179022-18-000044 · edgar.xml · nonDerivative · entry 5 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,914 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F4 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.18. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 59,700 | $0.87 | $51,939.00 |
DisclosureSEC source: 0001179022-18-000044 · edgar.xml · nonDerivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 9,500 | $2.32 | $22,040.00 |
DisclosureSEC source: 0001179022-18-000044 · edgar.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179022-18-000044 · edgar.xml · derivative · entry 6 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2022-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F2 · derivative.exercise_date: The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 50,000 | $5.00 | $250,000.00 |
DisclosureSEC source: 0001179022-18-000044 · edgar.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,914 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 50,000 | $2.32 | $116,000.00 |
DisclosureSEC source: 0001179022-18-000044 · edgar.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001179022-18-000040 · edgar.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: The options vest as follows: 25% on June 30, 2018, 25% on September30, 2018, and 50% on December 31, 2018. Read SEC document |
| January 15, 2018 Filed Jan 17, 2018 21:34 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $5.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000011 · edgar.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-01-15 F1 · derivative.exercise_date: The options vest as follows: 25% immediately, 25% on June 30, 2018, and 50% on December 31, 2018. Read SEC document |
| December 03, 2016 Filed Dec 6, 2016 22:10 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-16-000124 · edgar.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-12-03 F1 · derivative.exercise_date: The options vest as follows: 25% immediately, 25% on July 1, 2017, and 50% on December 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.